Provided by Tiger Fintech (Singapore) Pte. Ltd.

Immunovant, Inc.

17.49
-1.1000-5.92%
Post-market: 17.600.1100+0.63%19:38 EDT
Volume:1.90M
Turnover:34.23M
Market Cap:2.99B
PE:-6.41
High:19.06
Open:18.77
Low:17.39
Close:18.59
Loading ...

Company Profile

Company Name:
Immunovant, Inc.
Exchange:
NASDAQ
Establishment Date:
2018
Employees:
362
Office Location:
320 West 37th Street,6th Floor,New York,New York,United States
Zip Code:
10018
Fax:
- -
Introduction:
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.

Directors

Name
Position
Eric Venker
Chief Executive Officer and Director
Frank M. Torti
Executive Chairperson of board
Andrew Fromkin
Director
Atul Pande
Director
Douglas Hughes
Director
Jacob Bauer
Director
Robert Susman
Director

Shareholders

Name
Position
Eric Venker
Chief Executive Officer and Director
Melanie Gloria
Chief Operating Officer
Tiago Girao
Chief Financial Officer
Christopher Van Tuyl
Chief Legal Officer and Corporate Secretary
Frank M. Torti
Executive Chairperson of board
Jay S. Stout
Chief Technology Officer
Michael Geffner
Chief Medical Officer